Last reviewed: June 8, 2026

Last updated: June 8, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide has transformed weight loss treatment, with clinical trials showing an average 15% body weight reduction over 68 weeks in patients with overweight or obesity. Finding a trustworthy source matters: PlexusDx partners exclusively with licensed 503A compounding pharmacies to deliver pharmaceutical-grade semaglutide tailored to your individual metabolism and genetics. Unlike one-size-fits-all approaches, PlexusDx combines accessible pricing, genetic personalization, and expert clinical guidance.

Licensed Compounding Pharmacies: Why Source Matters

Not all semaglutide sources are equal. PlexusDx exclusively partners with licensed 503A compounding pharmacies—facilities regulated by state boards of pharmacy and federal law to manufacture medications on-site under strict quality standards. These pharmacies compound semaglutide to pharmaceutical purity using USP-grade materials, ensuring batch consistency and sterility that over-the-counter or unregulated suppliers cannot match.

503A compounding differs fundamentally from 503B manufacturing, which operates under different regulatory oversight. PlexusDx's 503A network undergoes routine inspections, maintains detailed records of ingredient sourcing, and follows patient-specific prescription protocols. This means your semaglutide injection or oral formulation is prepared specifically for you—not mass-produced in bulk—reducing contamination risk and allowing dose customization without the one-size approach of commercial products.

Semaglutide Dosing and Pricing: Transparent, Flat-Rate Access

PlexusDx's Compounded Semaglutide Injection starts at $149 per month across all commitment tiers—your dose may need to go up, but your price won't. This pricing model removes barriers for patients who need gradual dose escalation over weeks to minimize gastrointestinal side effects and optimize weight loss. Whether you begin at 0.25 mg or advance to 1.0 mg, the monthly cost remains consistent, supporting long-term adherence without surprise fees or dose-based billing.

Oral Semaglutide tablets offer an alternative for patients preferring non-injected therapy, starting at $249 per month. Both formulations qualify for HSA and FSA accounts, and PlexusDx serves all 50 states without requiring insurance coverage or membership fees. This accessibility model removes traditional gatekeeping that has historically limited semaglutide access to insured populations or those near major medical centers.

Genetic Personalization: The Precision Peptide Approach

PlexusDx's Precision Peptide Genetic Test ($99 add-on after your first month) analyzes 14 metabolic pathways across 49 peptides using 150+ genetic insights to predict how your body will respond to GLP-1 receptor agonists like semaglutide. Key variants—including GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313—influence appetite signaling, energy storage, and satiety responses. Understanding your genetic profile helps PlexusDx's clinical team optimize your starting dose, escalation timeline, and medication choice.

This peptide-pathway genetic testing differs from pharmacogenomic panels, which predict drug metabolism. Instead, it reveals which metabolic circuits drive your weight gain and which medications are most likely to engage them effectively. A patient with a genetic predisposition toward impaired GLP-1 receptor sensitivity may benefit from dual-compound therapy (GLP-Squared Injection, $249/mo) combining semaglutide with tirzepatide—a strategy personalized to your biology rather than guesswork.

Comparing Semaglutide to Tirzepatide and Dual Protocols

Semaglutide activates GLP-1 receptors, signaling fullness and reducing appetite in the brain and gut. Tirzepatide, PlexusDx's alternative, activates both GLP-1 and GIP receptors—a dual mechanism that recent trials suggest produces slightly greater weight loss (22% at highest doses versus 15% for semaglutide alone). PlexusDx's Compounded Tirzepatide Injection starts at $249 per month, while the GLP-Squared Injection combines both compounds in a single injection for $249 per month.

Your choice depends on your genetic profile, response to monotherapy, and tolerability. Patients who experience persistent nausea on semaglutide alone or demonstrate genetic variants associated with incomplete GLP-1 receptor engagement may see superior results with tirzepatide or dual therapy. PlexusDx's Precision Peptide Genetic Test informs this decision, helping your clinician select the most effective compound for your unique metabolism rather than trial-and-error dosing.

Side Effects, Safety Monitoring, and Clinical Support

GLP-1 medications cause nausea, vomiting, and constipation in a significant proportion of users—typically mild and transient with slow dose escalation, but worth monitoring. PlexusDx's model emphasizes gradual titration: your dose increases every 4 weeks if tolerated, allowing your body to adapt and reducing nausea risk compared to rapid escalation protocols. The Microdose GLP-1 Protocol ($129/mo) offers an entry-level option for patients sensitive to standard dosing, starting at sub-standard doses to minimize early side effects.

PlexusDx partners include clinical oversight: your prescription comes with access to licensed clinicians who review your progress, side effects, and weight loss trajectory. Unlike unregulated online pharmacies that deliver pills without follow-up, PlexusDx's model includes touchpoints for safety and efficacy monitoring. Serious risks—pancreatitis, thyroid concerns, or gallbladder issues—require medical supervision that compounding pharmacies alone cannot provide; PlexusDx's clinical network bridges this gap.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Precision Peptide Genetic Test starts at $99 add-on. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is PlexusDx's compounded semaglutide the same as Ozempic or Wegovy?

PlexusDx's semaglutide is compounded from pharmaceutical-grade materials by licensed 503A pharmacies and contains the same active ingredient as FDA-approved semaglutide products, but it is not FDA-approved as a finished medication. The clinical effect is equivalent when dosed properly, and it costs significantly less. PlexusDx's advantage is personalized dosing, genetic guidance, and flat pricing regardless of dose level.

How does the Precision Peptide Genetic Test improve my weight loss outcomes?

The test identifies your genetic predispositions across 14 metabolic pathways, revealing whether you have impaired GLP-1 receptor sensitivity, increased appetite drive, or other pathway variations. PlexusDx uses these insights to recommend semaglutide versus tirzepatide versus dual therapy, optimize your starting dose, and predict side effect risk. Patients with genetically guided therapy show higher adherence and satisfaction than those on standard protocols.

Can I use HSA or FSA funds to pay for PlexusDx semaglutide?

Yes. PlexusDx's compounded semaglutide, tirzepatide, and combination therapies are HSA and FSA eligible, allowing you to use tax-advantaged health savings to reduce out-of-pocket cost. The Precision Peptide Genetic Test is also eligible, making personalized therapy accessible to plan holders.

What if I live in a state with semaglutide restrictions?

PlexusDx serves all 50 states. State regulations vary regarding compounded medications, but licensed 503A pharmacies operate legally nationwide under state pharmacy board oversight. Your PlexusDx clinician ensures compliance with your state's regulations before dispensing.

Should I choose semaglutide or tirzepatide based on my genetic test results?

Your Precision Peptide results guide this decision: if your results show strong GLP-1 receptor sensitivity and no GIPR pathway impairment, semaglutide alone may be sufficient. If you have genetic variants suggesting GIP receptor involvement or impaired GLP-1 signaling, tirzepatide or GLP-Squared dual therapy typically produces better results. PlexusDx's clinicians interpret your results and recommend the best option for your biology.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves